Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

Key Points

• The aim is to assess the management strategies and outcomes associated with major bleeding incidents during treatment with dabigatran or warfarin.
• Reviewed clinical data from multiple trials including NCT00262600, NCT00291330, NCT00680186, NCT00329238, and NCT00558259.
• Examined outcomes related to major bleeding events while on anticoagulant therapy.
• Analyzed various management strategies employed during these incidents.
• Major bleeding occurred in a significant proportion of patients on both dabigatran and warfarin with noted differences in management outcomes.
• Outcomes were more favorable in certain management pathways compared to others, indicating potential for improved protocol adherence.
• Significant differences in bleeding event resolutions were observed depending on the anticoagulant used.